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Abstract
The objective of this project is to: 1) identify current understanding, attitudes, and beliefs
of clinicians at a midsized urban outpatient substance use treatment clinic regarding contingency
management (CM) treatment modality; 2) examine how this data contributes to barriers to
implementation of contingency management for methamphetamine treatment; and 3) make
recommendations to improve implementation strategies. A ten-question survey was developed
based on Social Ecological Theory (U.S. Department of Health and Human Services, 2005), and
was administered to 31 clinicians. A key informant interview was conducted using theoretical
sampling (LoBiondo-Wood & Haber, 2018) of emergent themes. Three major barriers emerged
from the data, including characteristics of methamphetamine use disorder, integration of CM into
agency process, and lack of client resources. Limitations of the study included a small sample
size, and limited representation of agencies. Recommendations include the administration of
client interviews to develop client centered, feasible solutions.
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Barriers to Contingency Management Implementation
Methamphetamine use is on the rise in America (DEA, 2020; Glick et al., 2018; Jones et
al., 2020a). In the United States, 1.9 million people age 12 and up report using
methamphetamines (Chawarski et al., 2020). According to the National Institute on Drug Abuse
(NIDA), methamphetamine overdose deaths have increased from 547 in 1999 to 16,167 in 2019
(NIDA, 2021). Furthermore, a cross-sectional study of approximately 1.3 million amphetaminerelated US hospitalizations between 2003 and 2015 showed that hospitalizations increased
substantially by 2015, and annual hospital costs related to amphetamines increased from $436
million in 2003 to $2.17 billion by 2015 (Winkleman et al., 2018). Administration via injection
has been increasing, as has concurrent use with opiates (Jones et al., 2020a).
In the western United states, over half of all substance use treatment admissions reported
to the Substance Abuse and Mental Health Services Administration (SAMHSA) were related to
methamphetamine, and between 2008 and 2016, overdoses related to methamphetamine
quadrupled in Washington State (Stoner et al., 2018). Locally, King County has seen a
substantial increase in methamphetamine use and overdose (Hood et al., 2018; Stoner et al.,
2018). In 2018, 54% of overdose deaths in King County involved a stimulant, and 40% of all
overdose deaths involved methamphetamine specifically (Hood et al., 2018; Stoner et al., 2018).
Methamphetamine use appears to be heavily concentrated in the unhoused or unstably housed
community, as well as among men who have sex with men (Banta-Green et al., 2017; BantaGreen et al., 2015; Stoner et al, 2018).
Chronic methamphetamine use can cause cardiovascular and cerebrovascular sequalae,
chronic psychosis, and cognitive impairment (Curran et al., 2004; Herron & Brennan, 2019;
Hsieh et al. 2014; Sadock et al., 2015). If injected, methamphetamine can increase a patient’s
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likelihood of contracting HIV or hepatitis C (Herron & Brennan, 2019; Sadock et al., 2015).
Methamphetamine use is also linked to lower retention rates in substance use treatment programs
and complicates the treatment outcomes of those concurrently using an opiate (Tsui et al., 2020).
These factors impact care, engagement, and outcomes for nurses, nurse practitioners, and their
patients.
Contingency management (CM) is an evidenced-based psychosocial intervention that is
effective in initiating abstinence. (McPhereson et al, 2018). CM is based in the behavioral
science of operant conditioning, i.e., rewarding abstinence with incentives such as money or
vouchers (Burduli et al., 2018; McPhereson et al., 2018). Despite its effectiveness, only 10% of
substance use treatment clinicians report using CM (Becker et al., 2019; Kirby et al., 2006).
Currently, minimal information exists on the barriers to implementing CM in clinical settings,
specifically as a treatment for methamphetamine use. This project seeks to understand these
barriers in order to improve implementation of CM.
Purpose and Aims
The purpose of this project is to determine the barriers to implementation of contingency
management at a mid-sized outpatient substance use treatment center. The specific aims are to:
1) identify clinicians’ understanding, attitudes, and beliefs regarding contingency management;
2) examine the clinical implementation of contingency management in methamphetamine
treatment; and 3) develop recommendations to improve clinical implementation of contingency
management.
State of the Science
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Literature searches were conducted on CINAHL, PubMed, PsycINFO, and Google
Scholar. Text sources were referenced to better explain addiction. Sources cited are less than five
years old, unless current research was not available, or to include an applicable landmark study.
Substance Use Disorder
Substance use disorders (SUDs) are characterized by a combination of behavioral,
psychological, and physical dependence (Sadock et al., 2015). Behavioral dependence is defined
by substance seeking activities, while psychological dependence refers to the cravings
experienced by a person who has become dependent on a substance. Physiological dependence
are the physical effects experienced by a person when they no longer have access to their
substance of choice. Sadock et al. (2015) note that no one person is guaranteed to develop a
substance use disorder. Instead, drug availability, social setting, specific actions of the drug, and
the likelihood of negative effects can all play a role in developing addiction. Dr. Nziga A.
Harrison (2020), an addictions psychiatrist, states the development and sustenance of this chronic
illness can be divided into four categories: biological causes, such as genetics or an acquired
illness; psychological causes, or how our world view developed; social and stress related causes,
such as how chronic and acute stressors can impact physiological reactions and decision making;
and the cultural and political causes, or how our ethnicity, sexuality, gender, religion, and
socioeconomic class impact our lives and health.
Terminology in addiction medicine varies. More commonly known terms, such as
“addict,” are considered stigmatizing. This author will attempt to use terminology from The
American Society of Addiction Medicine (ASAM) to reduce stigmatizing language around
addiction. Slang or colloquial terms will be avoided, and language that emphasizes the chronic,
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medical nature of substance use disorder will be prioritized. This author seeks to respect the lives
and journeys of those living with methamphetamine use disorder.
The biological and psychological elements of addiction can be seen as a process of
impulsivity and compulsivity (Stahl, 2013). Drug use of any kind can be considered “behavior
maintained through consequences” - be they biological, the reduction of withdrawal symptoms
or the euphoria of the high; psychological, the alleviation of cravings; or social, the approval of
the peer group (Sadock et al., 2015). Stahl (2013) notes that impulsivity and compulsivity further
maintain this process. Impulsivity can be conceptualized as the inability to “stop starting”
actions, with minimal critical thinking about consequences, while compulsivity is characterized
by the inability to stop ongoing actions and behaviors (Stahl, 2013). The habits one forms can be
a type of compulsion, as well as a conditioned behavior - stimulated by the environment and
mediated by positive or lack of negative reinforcement (Higgins & George, 2013; Stahl, 2013).
Stahl (2013) characterizes both impulsivity and compulsivity as a type of cognitive inflexibility,
mediated by a lack of cortical control over “bottom up” drives. These drives are neuronal loops,
influenced by the brain’s reward circuitry. With a substance use disorder, what may start as an
impulse that is mediated by reward circuits can ultimately become habituation, thereby
decreasing sensitivity to the pleasurable response, and requiring increased use to achieve the
same gratification (Higgins & George, 2013; Stahl, 2013).
Methamphetamine Use Disorder
According to ASAM, Methamphetamine is classified as a stimulant, differing from
amphetamine prescribed for conditions such as ADHD by a methyl group (Herron & Brennan,
2019). Herron and Brennan (2019) state that stimulants cause an increase in extracellular
dopamine and norepinephrine in both the central and peripheral nervous systems, and notes that
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stimulants have a wide array of uses, such as management of ADHD, or for anti-fatiguing and
performance enhancing properties. When prescribed, stimulants such as amphetamines are taken
orally, or transdermally, which mitigates some of the intense psychological effects that are seen
with smoking or injecting. These routes of administration are more rapidly absorbed, causing a
faster onset of pleasurable feeling, followed by a more rapid decline of effect.
Amphetamine and methamphetamine use can cause elation, euphoria, and alertness, but
increasing dose and use may cause these feelings to progress to dysphoria, irritability, and
psychotic symptoms that can be similar to the positive and cognitive symptoms of schizophrenia
(Sadock et al., 2015). A meta-analysis on methamphetamine induced psychosis conducted by
Hsieh et al. (2014) found that, depending on the study, methamphetamine induced psychosis can
occur from 10% to 60% of methamphetamine users, with the dose and frequency of use making
psychosis more likely. Furthermore, 30% of individuals who have experienced
methamphetamine induced psychosis found that these symptoms lasted longer than six months.
Chronic use of methamphetamine causes cognitive impairment, and even chronic psychosis, with
some theories proposing a kindling effect of chronic use leading to increased susceptibility to
developing a psychotic disorder (Curran et al., 2004).
According to Hsieh et al. (2014) the pathophysiology of this psychosis is believed to be
caused by an influx of dopamine in the limbic pathway— the bedrock of the dopamine
hypothesis of schizophrenia— as well as possibly relating to aberrant glutamatergic
transmissions, and subsequent damage to GABAergic neurons. The limbic system, along with
the ventral tegmental area and the cortex, form the reward circuit pathway that is stimulated by
many substances of abuse, and this can lead to habituation (Stahl, 2013).
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In addition to the aforementioned behavioral health concerns, there is an increased risk of
cardiovascular and cerebrovascular side effects for long term methamphetamine uses, with
hypertension and myocardial infarction becoming more likely (Sadock et al., 2015). Individuals
who inject methamphetamine are at a higher risk of contracting HIV and hepatitis (Herron &
Brennan, 2019; Sadock et al., 2015).
One barrier to methamphetamine use disorder treatment is the lack of effective
pharmacological interventions (Bhatt et al., 2016; Chan, et al., 2019). Medication treatments,
such as suboxone, naltrexone, or methadone, are shown to be incredibly impactful for those
living with opiate use disorder (Connery, 2015; Timko et al., 2016). This is not true of
medication treatments for methamphetamine use disorder—a recent meta-analysis found only
low strength evidence for methylphenidate and topiramate reducing methamphetamine use (Chan
et al., 2019). Further analysis of prescribed stimulants as a medication treatment for
methamphetamine found no effect for sustained abstinence (Bhatt et al., 2016). Both Chan et al.
(2019) and Bhatt et al. (2016) noted evidence of bias and methodological flaws in studies on
medication for methamphetamine use disorder. There will likely be continued research in this
area, but currently little evidence exists for effective pharmacological interventions for
methamphetamine use disorders (Bhatt et al., 2016; Chan, et al., 2019).
Nationally, methamphetamine use is on the rise (DEA, 2019; Glick et al., 2018; Jones et
al., 2020a). According to the Drug Enforcement Administration National Drug Threat
Assessment Reports (2020), deaths from methamphetamine use have been steadily rising since
2010. Jones et al. (2020a) report increases in administration via injection since 2008, along with
concurrent use of opiates, heroine, and benzodiazepines. The last decade has seen increases in
methamphetamine use among people using heroin and being treated for heroin use disorder
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(Jones et al., 2020a; Palamar et al., 2020). The 2015–2018 National Surveys on Drug Use and
Health (NSDUHs) estimated that those most likely to have used methamphetamine in the last
year were Hispanic and non-Hispanic white males, age 26 to 50 and older, with lower
educational attainment, Medicaid or no insurance, and those with co-occurring substance use
disorders and mental illness (Jones et al., 2020b).
The western United States has a long history with methamphetamine, and the nationwide
rise in use and negative sequelae is especially reflected there (DEA, 2020; Glick et al., 2018;
Stoner et al., 2018). In 2017, over half of all drug treatment admissions reported to SAMHSA
involved methamphetamine in the western US (Stoner et al., 2018). In a survey of Syringe
Exchange Programs (SEP) in Washington State, methamphetamine and heroin were the most
frequently used substances, with 82% of respondents saying they used methamphetamine alone,
and 46% reporting they combined it with an opiate (Banta-Green et al., 2018). Seattle
wastewater testing showed methamphetamine present at the highest levels of all cities tested
(Glick et al., 2018; Stoner et al., 2018).
Contingency management
Contingency management (CM) is a non-pharmacological intervention for
methamphetamine use, rooted in the behavioral science of operant conditioning (Burduli et al.,
2018). McPherson et al. (2018) writes that SUD is conceptualized as a behavior, the strength of
which is modified by reward or punishment. The premise of Contingency Management is to
modify this behavior by providing incentives to not use the substance of choice. Key principles
in the efficacy of CM include the amount of reinforcement per behavior, the immediacy at which
the reinforcement is delivered, and the size of the reinforcement. These reinforcements can take
the form of tangible items—money; vouchers; gift cards; social incentives, such as certificates;
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or clinic privileges, such as early dosing at a methadone clinic. Reinforcements can be negative,
such as revocation of previously allowed privileges or items. Notably, punishing reinforcements
can worsen detrimental behaviors, therefore CM programs largely use positive reinforcement
(McPhereson et al., 2018).
Contingency management is considered to be one of the most effective psychosocial
interventions for substance use disorder (De Crescenzo et al., 2018). Contingency Management
shows promise across cultures, and with underserved populations (McPherson et al., 2018;
Okafor et al., 2020). Several studies investigated CM efficacy among specific populations of
substance users, such as those who utilize syringe exchange programs, and men who have sex
with men (MSM) (Glick et al., 2018). These studies confirm that CM is effective in retention in
treatment and reduction in use, though long term abstinence is less clear (Minozzi et al., 2016).
Despite CM’s history as an empirically supported tool for substance use treatment, it is
among the least utilized (Rash et al., 2012). Several studies have investigated why it is
underutilized (Becker et al., 2019; Beneshick et al., 2010; Cameron & Ritter, 2007; Kirby et al.,
2006; Rash et al., 2012). Many of these studies utilize surveys, sent to clinicians working in the
field of substance use. While there are studies that look at specific populations of patients and
providers, such as at the Veterans Administration, this project will include surveys that restricted
poling to community-based SUD providers. The majority of practitioners surveyed in these
studies viewed CM favorably but acknowledged barriers to implementation (Kirby et al., 2006;
Rash et al., 2010).
Thematic findings included: 1) beliefs that CM doesn’t address underlying addiction, and
instead incentivizes behavior change (Kirby et al., 2006); 2) beliefs that conflict between patients
could arise due to unequal incentives (Kirby et al., 2006); 3) prohibitive cost of implementation
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(Kirby et al., 2006; Rash et al., 2010); 4) time constraints to implement CM (Beneshik et al.,
2010); 5) differences between CM and the agency’s philosophy of treatment (Beneshik et al.,
2010); and 6) beliefs that substance use returns once CM is withdrawn (Rash et al., 2010).
Kirby et al., (2006) note that factors that positively influenced provider’s beliefs about
CM included: 1) expertise and experience with CM; 2) having a supervisory role; 3) holding an
advanced degree; and 4) more years of experience in the field of chemical dependency. Rash et
al. (2012) assessed whether allegiance to an alternate treatment modality served as a barrier to
CM implementation but did not find it to be a primary.
At the same time prevalence and lethality is increasing, there is minimal research on
exploring barriers for treatment of methamphetamine use disorder. This project further expands
upon the research on barriers to CM implementation in outpatient substance use disorder clinical
settings, specifically around methamphetamine use.
Theoretical Framework
Social Ecological Theory
The social ecological framework conceptualizes how behavior affects, and is affected by,
multiple levels of influence—from personal to political (U.S. Department of Health and Human
Services, 2005). The social environment in which one lives, works, and coexists impacts
behaviors. Examining public health from this perspective is one way to view structural
circumstances and the impact on health behavior. This can guide multiple levels of intervention
(U.S. Department of Health and Human Services, 2005).
The social ecological model examines public policy, community, organizational,
interpersonal, and individual factors (see figure 1). The U.S. Department of Health and Human
Services (2005) describes public policy as the federal, state, or local laws that impact health

BARRIERS CONTINGENCY MANAGEMENT IMPLEMENTATION

12

behaviors. Furthermore, community factors refer to norms existing among individual’s social
circles to inform actions or behaviors about healthcare. Each community is unique, and may be
defined by geographic location, religion, race, or ethnicity. The organizational level examines
rules, regulations, policies, and work culture within an organization impacting behaviors of
clients or employees (Rural Health Integration Hub, n.d). The interpersonal level examines how
interactions with other individuals may support or create barriers to healthcare, whereas at an
individual level, the effects of one’s own knowledge, attitudes, beliefs, and personality are
considered (Rural Health Integration Hub, n.d). These levels can be conceptualized as cognitivebehavioral influence, as they examine the relationship between how one’s thoughts mediate
actions, and how one’s environment, perceptions, skills, and knowledge impact those actions
(U.S. Department of Health and Human Services, 2005).
The social ecological framework has been used as a tool in substance use disorder
research, specifically factors that influence the opiate epidemic in America (Jalalai et al., 2020).
It is useful to examine factors in substance use that exist outside individual decision-making. In
the same way, it is helpful to examine potential barriers to CM implementation at the clinical
level by examining different levels of influence impacting a clinician’s willingness or ability to
use this intervention.
Figure 1
Social ecological levels of influence
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(Ganz, 2010)
Harm Reduction
Harm reduction incorporates a spectrum of beliefs about substance use and does not
endorse abstinence as the only path to recovery. The National Harm Reduction Coalition (2020)
states that harm reduction seeks to accept that substance use is a part of this world, is influenced
by many complex factors, and the quality of the lives of individuals with substance use disorder
is more important than total abstinence. Harm reduction is based on respect and positive regard
for clients who use substances (National Harm Reduction Coalition, 2020). Studies commonly
use complete cessation of methamphetamine use as the metric for successful intervention.
Similarly, urine screening is not an ideal tool for gauging use reduction or less risky routes of
administration. Harm reduction used as a value framework reinforces the difference between
research and practice, which ultimately impacts client recovery.
Methods
Design
This project assesses barriers to contingency management implementation for
methamphetamine use in an outpatient setting. This quality improvement project consists of a
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ten-question online survey collecting qualitative and quantitative data. Both Likert scale and
multiple choice questions were utilized, with open-ended text options available to capture
information not evoked by multiple choice options. (See Appendix B).
An additional arm of research focused on key informant interviews to examine the
themes that emerged from the survey results. These questions were developed through the
process of theoretical sampling (LoBiondo-Wood & Haber, 2018). Survey questions and
interview responses were analyzed for understanding, attitudes, and beliefs regarding CM for
methamphetamine use.
Setting
This project was set at a mid-sized non-profit agency that offers substance use disorder
treatment and social services. Clinicians at three clinical locations of this agency were invited to
take the survey.
Participants and Recruitment
There are two groups of project participants. The first group consists of approximately 40
frontline clinicians who complete the intake process with clients, and who may refer clients into
CM programs at their organization. These counselors have the minimum qualifications of
academic training and work experience in the social service field, as well as a current Substance
Use Disorder Professional (SUDP) license. The second group includes clinicians experienced in
contingency management, selected based on guidance from site contacts and interviewed as key
informants to expand upon data gathered in the survey.
Email invitations were sent to the frontline clinicians by the site coordinator. Informed
consent was obtained prior to participation. All responses were de-identified to protect the
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privacy of the respondents. No minors, patients or vulnerable populations were involved in this
study.
Minimal possible risk to anonymity inherent in small organizations was mitigated by the
Primary Investigator (PI) by using a secondary coder not affiliated with the organization, and not
collecting indirect identifiers, such as demographics or clinic location. Seattle University
Institutional Review Board (IRB) identified this as a quality improvement project, which meets
exempt status.
Instrument
This project utilized a ten-question survey composed of multiple choice and Likert Scale
questions. Likert Scale questions were chosen in order to assess levels of understanding and
comfort with CM. Multiple choice questions were chosen to explore individual, interpersonal,
organizational, and community areas that may hold barriers CM implementation. Open-ended
options within the multiple choice questions were included to capture a wider scope of potential
barriers. The Pew Research Center Questionnaire Design (n.d.) and Harvard University Program
on Survey Research (Harrison, 2007) were utilized for survey development. Question
development was further guided by existing data on barriers to contingency management
implementation (Kirby, 2006), as well as articles on the social ecological framework (Jalalai et
al., 2020; Rural Health Integration Hub, n.d.).
Informed consent was obtained and the survey was disseminated through Google Forms
(See Appendix B). Introduction and instructions were in the body of the email that included a
link to the survey (See Appendix A).
Data Analysis
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Quantitative data was analyzed using pivot tables on Excel. Open ended questions and
interviews were coded by hand, grouping answers to each question by emergent themes.
Independent secondary coding was performed on qualitative data, to ensure accuracy of themes
and anonymity of respondents. Key informant interviews were coded based on thematic content.
Results
Thirty-one individuals completed the survey, and one key informant interview was
conducted. The following survey results are displayed by item.
Table 1
Barriers at the public policy level.
Methamphetamine use has been identified as a serious issue at public
policy level.

%

n

Strongly agree

35.48%

11

Agree

32.26%

10

Disagree

22.58%

7

Neutral

6.45%

2

Strongly disagree

3.23%

1

100.00%

31

Grand Total
Table 2
Barriers at the community level
CM for methamphetamine is applicable to our patient population.

%

n

Strongly agree

64.52%

20

Agree

25.81%

8

Neutral

6.45%

2

Disagree

3.23%

1

100.00%

31

Grand Total
Table 3

BARRIERS CONTINGENCY MANAGEMENT IMPLEMENTATION

17

Barriers at the community level
What do you perceive to be the most important barrier to CM
implementation at the community level?

%

n

Our clients' housing status makes participating in CM challenging

38.71%

12

There is a lack of knowledge from outside service providers about CM

16.13%

5

It is too hard for our clients to get to the clinic twice a week
Our clients' community of family, friends, and children makes participating in
CM challenging

16.13%

5

12.90%

4

Other- write in

9.68%

3

There is no barrier at the community level

6.45%

2

100.00%

31

Grand Total
Table 4
Barriers at the organizational level
My organization views CM as an evidenced based approach to
methamphetamine use.

%

n

Agree

48.39%

15

Strongly agree

29.03%

9

Neutral

19.35%

6

Disagree

3.23%

1

100.00%

31

Grand Total
Table 5
Barriers at the organizational level
What do you perceive to be the most important barrier to CM
implementation at the organization level?

%

n

Integration into workflow

35.48%

11

Referral process

12.90%

4

Staff training

12.90%

4

Other- write in

16.13%

5

Staff knowledge

9.68%

3

There is no barrier at the organizational level

6.45%

2

Culture of the organization

6.45%

2
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100.00%

31

%

n

Table 6
Barriers at the intrapersonal level
What do you perceive to be the most important barrier to CM
implementation at the interpersonal level?
CM may work for some clients but not others

64.52%

20

Other- write in

9.68%

3

Confidence in colleague ability to implement CM

9.68%

3

Not all clients trust their counselors enough to participate

6.45%

2

There is no barrier at the community level

3.23%

1

Not all counselors trust their clients to complete CM

3.23%

1

Not all clients trust their providers enough to participate

3.23%

1

100.00%

31

Grand Total
Table 7
Barriers at the individual level
I generally view CM as an evidenced based approach to
methamphetamine use.

%

n

Agree

41.94%

13

Strongly agree

25.81%

8

Neutral

25.81%

8

Strongly disagree

3.23%

1

Disagree

3.23%

1

100.00%

31

Grand Total
Table 8
Barriers at the individual level
What do you perceive to be the most important barrier to CM
implementation at the individual level?

%

n

There is no barrier at the individual level

51.61%

16

Other- write in

19.35%

6
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I already feel like I have too much work to add CM

16.13%

5

I don’t have adequate training

12.90%

4

100.00%

31

Grand Total
Table 9
Likelihood to refer clients to contingency management
Based on your answers above, how likely are you to refer a patient to CM.

%

n

Very likely

70.00%

21

I'm not sure

16.67%

5

Somewhat likely

13.33%

4

100.00%

30

Grand Total
Discussion

The findings of this project demonstrate both aims one and two were met, and provided
sufficient data to make the following recommendations.
The first aim identified clinicians’ understanding, attitudes, and beliefs regarding CM at a
midsized outpatient substance use treatment clinic. CM was favorably regarded by clinicians (see
Tables 2, 7, and 9). This replicates the findings of Kirby et al. (2006), who surveyed 383
substance use treatment clinicians, and suggests that barriers to CM implementation are not
primarily at the individual level. The majority of the respondents endorsed that their agency
viewed CM as evidenced based (see Table 4).
The second aim examined barriers to clinical implementation of contingency
management in methamphetamine treatment. Three barriers identified included: 1)
characteristics of methamphetamine use disorder; 2) integration of CM into agency process; and
3) lack of client resources.
Perceptions that methamphetamine use itself creates challenges to implementation
appeared multiple times. Challenges noted in the open-ended responses included how
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methamphetamine use made it difficult for patients to engage in treatment. Similarly, Tsui et al.
(2020) observed that methamphetamine use reduced retention rates in concurrent treatment for
opiate use disorder. Furthermore, McPherson et al. (2018) noted that participants who had a
positive urinalysis for a stimulant achieved a shorter period of abstinence with CM.
Respondents indicated an assumption that active methamphetamine use made rewardbased abstinence less valuable. In a 2016 meta-analysis of barriers to accessing treatment for
methamphetamine use disorder, a common barrier to accessing treatment included client’s
feeling that treatment was unnecessary (Cumming et al., 2016). Clinicians and the key informant
observed how many individuals using methamphetamine do not recognize their use as
problematic. This can be contrasted with a finding in the Kirby et al. (2006) study illustrating
respondents’ belief that CM does not address underlying issues of substance use.
Lack of resources such as housing and access to transportation represent the second
barrier (see table 3). Limited access to transportation and housing instability may negatively
impact their treatment goals. McPherson et al. (2018) noted CM improved quality of life and
rates of abstinence for individuals in underserved communities, however the absence of basic
needs is still a barrier to initiating treatment. Interestingly, Becker et al. (2019) noted that higher
perceived client barriers correlated with lower CM adoption rates.
Agency process was another notable barrier (see table 5). Specific barriers in agency
process include: 1) adequate staffing and training; 2) difficulty integrating CM into clinicians’
pre-existing workflow; 3) deceptive simplicity of CM programs. As the key informant observed,
CM programs seem simple, but require preparation and detail to implement correctly. This can
be contrasted with Kirby et al (2006) finding CM viewed more favorably by those having greater
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experience with it as a treatment modality, and thus increased familiarity utilizing CM as a
treatment method. Cost was not reflected as a major barrier, unlike in Kirby et al. (2006).
Recommendations
Three recommendations emerged from the data: 1) interview clients who use
methamphetamine regarding their experience of barriers to treatment. Interviewing clients would
provide enhanced perspective on the unique challenges of treating methamphetamine use
disorder, and promote client centered solutions; 2) create a multidisciplinary workgroup to
address barriers within the agency itself, improving CM implementation at this clinic; 3) expand
utilization of this tool to other agencies interested in CM, thus providing information that is
tailored to their demographic.
Conclusions
Methamphetamine use is a deadly problem increasing in severity in the western United
States, particularly in the Seattle area (DEA, 2019; Glick et al., 2018; Jones et al., 2020a; Stoner
et al., 2018). The negative effects of methamphetamine use are wide ranging and will affect the
treatment outcomes for many clients of nurses and nurse practitioners (Curran et al., 2004;
Herron & Brennan, 2019; Hsieh et al. 2014; Sadock et al., 2015). This project aims to examine
why the effective intervention contingency management is rarely used to combat
methamphetamine use disorder at outpatient substance use treatment clinics. Results show the
clinicians surveyed regard CM favorably, suggesting barriers to implementation are influenced
by circumstances outside the individual. The identified barriers of agency process, lack of
resources, and characteristics of methamphetamine use itself demonstrate these internal and
external factors. Root causes of barriers to contingency management can be explored in future
projects, which will ideally gather data at diverse substance use treatment agencies. Likewise,
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clients who potentially benefit from this treatment modality should be interviewed. Increasing
understanding of the complex issue of methamphetamine use will help identify the structures that
contribute to individual actions and create solutions that will benefit not only members of our
local community, but also the millions of Americans who struggle with methamphetamine
disorder.
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Appendix A
Email Introduction and Link to Survey
Hello, my name is Emma Nauman, I’m a student at Seattle University in the Doctor of Nursing
Practice Program (DNP).
Thank you for completing this survey as part of my DNP research project. This brief survey
seeks to understand barriers to contingency management programs in an outpatient setting.
Contingency Management (CM) is a treatment for substance use disorder that utilizes rewards
for goal-oriented behavior - completing the intake process, providing a negative urine screen,
and so on. The rewards can be monetary, vouchers, special privileges at the clinic, or certificates
congratulating the clients on their hard work.
The survey is structured to analyze potential barriers in the following areas:
Policy: Public policy factors refers to laws that support disease prevention and management.
Community: Community factors refer to social norms that exist among the client or employee’s
social circle that inform actions or behaviors about healthcare.
Organization: Rules, regulations, policies, and work culture within an organization impacting
behaviors of client or employee.
Interpersonal: Interactions with other individuals that may support or create barriers to
healthcare.
Individual: One's own individual knowledge, attitudes, beliefs, and personality.
This survey should take 5-10 minutes, and can be accessed at the link here:
https://docs.google.com/forms/d/e/1FAIpQLScfk--7FMEJGP1wUisqbFmBclbIW9SmJwi6146YhUA6JVqYA/viewform?usp=sf_link
Thank you again, your participation is very much appreciated! Please feel free to reach out to me
with any questions or concerns.
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Appendix B
Informed Consent and Survey
You are being asked to complete a brief online survey in a research project. The project seeks to
investigate barriers to implementation of Contingency Management at a clinical level. Please
answer each question to the best of your ability. There is little risk associated with this study.
This is an anonymous survey. Your name, position, and clinic location will not be asked. All
research materials and consent forms will be stored electronically and will be accessible only by
the student researcher. Your participation in this study is voluntary. You may withdraw your
consent to participate at any time without penalty. A summary of the results of this research will
be supplied to you, at no cost in June 2021. Should you have any concerns about your
participation in this study, you may call Emma Nauman, the student researcher, at 503-890-2734.
If you have any concerns that your rights are being violated, you may contact the Seattle
University Institutional Review Board at (206) 296-2585. If you agree to complete this survey,
please select YES below.
Yes
Methamphetamine use has been identified as a serious issue at policy level
Strongly agree
Agree
Neutral
Disagree
Strongly Disagree
CM for methamphetamine is applicable to our patient population
Strongly agree
Agree
Neutral
Disagree
Strongly Disagree
What do you perceive to be barriers to CM at the community level?
Our clients’ community of family, friends, and children makes participating in CM
challenging
Our clients’ housing status makes participating in CM challenging
Our clients’ interactions with law enforcement make participating in CM challenging
There is a lack of knowledge from outside service providers about CM
It is too hard for our clients to get to the clinic twice a week
There is no barrier at the community level
Other – write in
My organization views CM as an evidenced based approach to methamphetamine use
Strongly agree
Agree
Neutral
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Disagree
Strongly Disagree
What do you perceive to be barriers to CM at the organizational level
Referral process
Staff training
Staff knowledge
Philosophy of the organization
Culture of the organization
Integration into workflow
There is no barrier at the organizational level
Other – write in
What do you perceive to be barriers to CM at the interpersonal level
Not all clients trust their counselors enough to participate
Not all clients trust their providers enough to participate
Not all counselors trust their clients to complete CM
Confidence in colleague ability to implement CM
CM may work for some clients but not others
CM rewards may cause jealousy between clients
There is no barrier at the interpersonal level
Other – write in
I generally view CM as an evidenced based approach to methamphetamine use
Strongly agree
Agree
Neutral
Disagree
Strongly Disagree
What do you perceive to be barriers to CM at the individual level
I don’t have adequate training
I already feel like I have too much work to add CM
I disagree with CM for methamphetamine treatment for moral reasons
I disagree because I think another approach works better
There is no barrier at the individual level
Other – write in
Based on your answers above, how likely are you to refer a patient to CM.
Very likely
Somewhat likely
I’m not sure
Somewhat unlikely
Very unlikely
What did we miss?
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Please share additional comments regarding clinician barriers to Contingency Management
for methamphetamine treatment
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